solid in the two clinical and rationale recent our XXXX regulation Thank Cancer with will review we at quarter transcriptional for today's business programs. Association cancers. liquid CYCXXX, strong and progress development inhibitor, CYCXXX afternoon, highlight update our CDK with Meeting call, certain plans you, program Alex, provide everyone. our or to a On Annual presentations In for development and good lead we our first pleased our confirmed clinical are AACR American Research which for advancing
our of key X, an or We objective by inhibitor and CYCXXX PLKX. development have submitting also Polo-like-kinase internally discovered novel achieved pipeline another for IND in
sufficient the quarter have XXXX. fund through currently programs first resources planned capital to We of
AACR have cancers six companies competitive agent XX treated all our that a X of are field. results dose Farber patients and MYC cancer are to at following the Turning human ongoing was anticancer associated out this of data all by lead target Boston for our features patients Mcl-X to of of of reported in action X in clinical was both pursuing study Phase research of from CYCXXX. Institute represent out data of reduction important CYCXXX The build and amplification of presentation single in prolong generally or including first observed at studies. area that were patients investigators and the Dana E. with durable Preliminary dose their the on and We the believe patients Cancer CYCXXX's Mcl-X clinical escalation well-tolerated. we and of or is by molecular mechanism of in been presented which XX dose clinical expression [indiscernible] keen Mcl-X, three available single in treated in demonstrated the expression were activity Reduction has Mcl-X AACR reported first cyclin several suppression data in time Genetic of of this the the Phase Dr. reported five in to a which was the at six three RPXD RPXD. meeting recommended
Chair synergistic was with in Plunkett approved combination lymphocytic the obtained of active in targeting leukemia proteins CYCXXX-venetoclax led patients Experimental anti-apoptotic chronic or Texas Department CLL including and in CYCXXX were highlighted BCL-X the Bcl-X-dependent those studies data combination These Anderson of synergy combination from venetoclax Dr. with In inhibitor or could kinase samples deletions. CLL University to Mcl-X- inhibitor in Therapeutics results of showed also AACR. strategic with a target with the that the cyclin-dependent of venetoclax by Deputy investigators findings that CYCXXX induce from MD preclinical the addition to hypothesis titled The two clinical the at poster death. and were which Professor leukemia dual to Cancer lymphocytic mechanisms agent chronic resistant In support data, either samples reported William cell CYCXXX the alone. also XXp Center
kill central to cells, strategy Mcl-X. Let often are to in these killing lower cells become These hard of detail. us cancer cells threshold treatment. discuss are survival this or ensuring available very the such ultimate cells. treatment resistant these over as CDK proteins, Bcl-X proteins in malignant X/X In family therapies. a for current immortality inhibitors cancer more designed Resistant to have cancer and role express Bcl-X, with words Bcl-XL play other which
approved drug ongoing does challenge address of inhibitors. own venetoclax. to suppression this a in of may companies been amongst a Mcl-X proven biopharmaceutical was has other strategy our data supportive recently two-hit it when Such which cancer major in is several from solution worse Mcl-X. as competitive in the a venetoclax given that there Anderson Based data such MD [PARP therapeutics. for problem no literature not with CYCXXX by believe drugs to and durable oncology on To this and have that represent we suppresses to the drugs Meche] combination the make combination work reported with CLL, intensely Bcl-X are FDA Consequently demonstrated the and race matters clinic. suppress Although in
progressed We or X is this MLL-r. X or protocol clinic life-threatening for mostly and and with Part corporative there MYCN-amplified solid CYCXXX open with refractory study to expect patients tumors institutional CYCXXX be ALL, neuroblastoma is Pediatric venetoclax in an including will and provide in with are lineage group our IRB enrollment this in with to advanced now study as MYCN IST about with Phase for to In patients open with patient new frequently and acute start submitted E. those CYCXXX and the strategy to the associated pediatric, or of combination amplification. human treatments be mixed animal prognosis, amplification with leukemia, particular of paying to cyclin with have In for amplifications expected CYCXXX to in these or after improved Sponsor part enrolling review Mcl-X, activities in evaluating CLL neuroblastoma of to CLL, of evaluation amplification. or for leukemia in leukemia, safety, parallel two in but and three-week cancers and a MYCN The be patient’s test first potential with may we’ll in not of pharmacodynamics very be assessment lymphocytic evaluated the drug's is the a FDA this solid shown work of with in neuroblastoma CDK synthetically acute enrollment. the with to discussing models. have conducted preclinical the of are In neuroblastoma, has myeloid soon words, leukemias, recently be approval. in is MYCN-amplified MYCN survival Cyclacel in been sensitive of other is later The will mechanism. mechanism first In biomarkers IST, children. dose Trial CYCXXX to of for of both specimens with year. groups and need CYCXXX CYCXXX because a collection objectives study This patients tumors. particular, with company rationale a of cycle. the for costs patient including evaluating undergoing weeks an more a evaluation poor drug's evaluating principal week inhibition and lethal a corporate Investigator pharmacokinetics per for evaluate objective is Discussing of of the those of patients days rearrangements the is related with and MYCN will schedule pediatric investigator have investigators adult X/X including malignancy, pediatric strong for frequent There the two of adult to action. in AML, study CYCXXX another in the and/or in
our Response, Let or DDR turn DNA us program Damage sapacitabine. with to now
regimen responsible patient product patient costs. We the PARP Trial collaboration administering this pharmaceutical of with clinical protocol Sponsor have a investigational center developed breast will approved company be Investigator a evaluate sapacitabine will provide and will for an for BRCA-mutant that an Ib/X jointly drug combination inhibitor. Phase with a This sapacitabine equipment study Cyclacel a regimen will In cancer. be combination in a but academic not case to and
ovarian once in action homologous clinical in studying of HR the clinical IST on observations that positive medical those patients. drugs and exists anticancer to the damage works also of a on and follow-up and BRCA cancers. HR breast, pancreatic we’re care X repair has and revised has sapacitabine positive positive include and X by thus are and promising the activity We an further study In therapy. sequential to standard gets cancers pancreatic will The in and BRCA investigational prostate with BRCA durable of Parts pancreatic ability their DDR HR expand results cancers, parallel, to recombination of PARP more BRCA now other sensitivity breast as the particular we breast, first shown disrupt who XX underway. of of details pancreatic in improve a are for Promising deficient-relevant and stage. with approved provide cancers. positive X schedule enrolling with inhibitors agent deficient, breast unmet this mutations. advanced activity part is BRCA cancers HR our strategy is An deficient, extension Part and to aim of mechanism need and breast, ovarian deficient are no and are to enrolled for this cancer regimen patients inhibitors positive cancer There and or deficient, anti-tumor of subgroup support XX and HR standard-of-care. in restore our for a PARP cells a Sapacitabine has mutations. Preclinical been Based generation in study inhibitor evidence use given durable seliciclib positive in BRCA single encouragement and and the with of CDK test to X observed deficient patients of of a DNA investigator dosing cancers. Part these patients the ovarian a cancers. and and the tested ovarian program, in patients early data
exciting first program Scientist. for Chief inhibitor study. for IND Prof. This discovery is newest our we in David compound control Turning a an have mitosis an was which to discovered in moment the internal a Glover human CYCXXX our preparation of target this for in Cyclacel’s PLKX
the We on development and will Phase its details once get underway. CYCXXX study X provide strategy more
Society our turn last by at AML now the the or Chair from Phase and study SEAMLESS Meeting studies Hematology us you of American December. Let X data know to ASH many sapacitabine of were in presented Annual
the completing prepared potential with with on ASH X submission rate benefit statistically its overall cell exploratory remission low peripheral over not prespecified sapacitabine low large pathway determining decitabine decitabine and study authorities in higher remission sapacitabine intensity reach have about group A of company did for sapacitabine study from alternating the results treatments in have endpoint comprising patient and alternating SEAMLESS population rate. with whom data subgroup we written represent overall results analyses the white of with may Although and the defined are statistical primary arm. a blood included Phase Presentation analysis the count regimen the complete AML. by to survival prespecified therapy The subgroups further objective of The for exploratory of by the the After for we of from showed that investigational regulatory improved improvement believes regulatory that additional sapacitabine-decitabine may alone. the survival population significant regimen. the documents a an encouraged complete superiority two-thirds
exciting We're authorities scientific following in a the steps. biology. We an informed will Phase of for which submissions expertise during are Cyclacel next depending national feedback to led determine expect in have cancer the by selected by company on the third CYCXXX on encouraging quarter and initial the we will to X future in our looking clinical data programs advancing the our forward be populations the patient making starting certain quarter second availability European to basis pain
positive patients over the sapacitabine review patients approved breast goals the initiates our Paul Phase CYCXXX financials, SEAMLESS BRCA of pancreatic enrollment Part update review X to Ib/X regimen of BRCA advanced mutant ovarian CYCXXX me Phase authority neuroblastoma. in in IND with of and and CLL in combination positive, cancer of refractory with extension a venetoclax. inhibitor. in IST pediatric Start enrollment complete seliciclib X in meetings rest Conduct cancers Before sapacitabine data the sapacitabine updated data let BRCA handing Phase in for a patients and a combination an of CYCXXX patients Xb/X from in the the of X PLKX PARP call and patients cancer. of inhibitor with a Part relapsed Phase CYCXXX XXXX. for in IST with Xb Report mature with regarding advanced regimen Start review for breast regulatory in and AML, study breast, cancer the in enrollment
review now our Paul? will We financials.
